Apri 28 Day NDC 50090-2481

NDC codes

FDA NDC Directory

Product NDC (as listed)50090-2481Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50090-2481Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50090-2481-0	50090248100	1 KIT in 1 KIT (50090-2481-0)Marketed from Oct 6, 2016

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Apri 28 DaySuffix: 28 Day
Generic name (nonproprietary): desogestrel and ethinyl estradiol
Dosage form: Kit
Labeler: A-S Medication Solutions
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 075256
Marketing start: Oct 22, 1999
Listing expires: Dec 31, 2026
Identifiers: Product ID 50090-2481_0acc2ce5-fb3e-4bd2-89eb-bde74305446aSPL ID 0acc2ce5-fb3e-4bd2-89eb-bde74305446aSPL set ID 3448d121-d00a-4752-8782-416b7a376f3fRxCUI 240707, 748797, 749848, 753482

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N450090248100 followed by a unit qualifier and the quantity

Package 50090-2481-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 12, 2024.

Indications (excerpt from the label)

INDICATIONS AND USAGE Apri ® (desogestrel and ethinyl estradiol tablets USP) is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the Norplant System depends upon the reliability with which they are used. Correct and consistent use of these methods can result in lower failure rates. In a clinical trial with Apri (desogestrel and ethinyl estradiol tablets USP), 1,195 subjects c…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 075256

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 075256
Product	Strength	Form · route	Labeler	Product NDC
Reclipsen 28 Daydesogestrel and ethinyl estradiol	—	Kit	Teva Pharmaceuticals USA, Inc.	0093-3304
Apri 28 Daydesogestrel and ethinyl estradiol	—	Kit	Teva Pharmaceuticals USA, Inc.	0555-9043